Hongxia Wang1,2, Dan Jiang1,2, Liyuan Liu2, Yanting Zhang2, Miao Qin2, Yuliang Qu2, Liyan Wang2, Shan Wu2, Haijin Zhou1, Tao Xu1, Guangxian Xu1,2. 1. Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, People's Republic of China. 2. School of Clinical Medicine, Ningxia Medical University, Yinchuan, People's Republic of China.
Abstract
Purpose: Due to the natural advantages of spermidine in immunity, we investigated the effects of spermidine pretreatment on nanobody-based CAR-T cells (Nb CAR-T) mediated cytotoxicity and potential mechanism. Patients and Methods: The optimal concentration of spermidine was determined by detecting its impact on viability and proliferation of T cells. The phenotypic characteristic of CAR-T cells, which were treated with spermidine for 4 days, was examined by flow cytometry. The expansion ability of CAR-T cells was monitored in being cocultured with tumor cells. Additionally, CAR-T cells were stimulated by lymphoma cells to test its cytotoxicity in vitro, and the supernatant in co-culture models were collected to test the cytokine production. Furthermore, xenograft models were constructed to detect the anti-tumor activity of CAR-T cells in vivo. Results: The optimal concentration of spermidine acting on T cells was 5μM. The antigen-dependent proliferation of spermidine pretreatment CD19 CAR-T cells or Nb CAR-T cells was increased compared to control. Central memory T cells(TCM) dominated the CAR-T cell population in the presence of spermidine. When spermidine pretreatment CAR-T cells were stimulated with Daudi cells, the secretion of IL-2 and IFN-γ has been significantly enhanced. The ability of CAR-T cells to lysis Daudi cells was enhanced with the help of spermidine, even at higher tumor loads. Pre-treated Nb CAR-T cells with spermidine were able to control tumor cells in vivo, and therefore prolong mice survival. Conclusion: Our results revealed that spermidine could promote Nb CAR-T mediated cytotoxicity to lymphomas cells through enhancing memory and proliferation, and provided a meaningful approach to strengthen the anti-tumor effect of CAR-T cells.
Purpose: Due to the natural advantages of spermidine in immunity, we investigated the effects of spermidine pretreatment on nanobody-based CAR-T cells (Nb CAR-T) mediated cytotoxicity and potential mechanism. Patients and Methods: The optimal concentration of spermidine was determined by detecting its impact on viability and proliferation of T cells. The phenotypic characteristic of CAR-T cells, which were treated with spermidine for 4 days, was examined by flow cytometry. The expansion ability of CAR-T cells was monitored in being cocultured with tumor cells. Additionally, CAR-T cells were stimulated by lymphoma cells to test its cytotoxicity in vitro, and the supernatant in co-culture models were collected to test the cytokine production. Furthermore, xenograft models were constructed to detect the anti-tumor activity of CAR-T cells in vivo. Results: The optimal concentration of spermidine acting on T cells was 5μM. The antigen-dependent proliferation of spermidine pretreatment CD19 CAR-T cells or Nb CAR-T cells was increased compared to control. Central memory T cells(TCM) dominated the CAR-T cell population in the presence of spermidine. When spermidine pretreatment CAR-T cells were stimulated with Daudi cells, the secretion of IL-2 and IFN-γ has been significantly enhanced. The ability of CAR-T cells to lysis Daudi cells was enhanced with the help of spermidine, even at higher tumor loads. Pre-treated Nb CAR-T cells with spermidine were able to control tumor cells in vivo, and therefore prolong mice survival. Conclusion: Our results revealed that spermidine could promote Nb CAR-T mediated cytotoxicity to lymphomas cells through enhancing memory and proliferation, and provided a meaningful approach to strengthen the anti-tumor effect of CAR-T cells.
Authors: Parvin Akbari; Afroditi Katsarou; Roxanna Daghighian; Lotte W H G van Mil; Elisabeth J M Huijbers; Arjan W Griffioen; Judy R van Beijnum Journal: Biochim Biophys Acta Rev Cancer Date: 2022-02-22 Impact factor: 11.414
Authors: Charly R Good; M Angela Aznar; Shunichiro Kuramitsu; Parisa Samareh; Sangya Agarwal; Greg Donahue; Kenichi Ishiyama; Nils Wellhausen; Austin K Rennels; Yujie Ma; Lifeng Tian; Sonia Guedan; Katherine A Alexander; Zhen Zhang; Philipp C Rommel; Nathan Singh; Karl M Glastad; Max W Richardson; Keisuke Watanabe; Janos L Tanyi; Mark H O'Hara; Marco Ruella; Simon F Lacey; Edmund K Moon; Stephen J Schuster; Steven M Albelda; Lewis L Lanier; Regina M Young; Shelley L Berger; Carl H June Journal: Cell Date: 2021-12-02 Impact factor: 66.850
Authors: Christina Amatya; Melissa A Pegues; Norris Lam; Danielle Vanasse; Claudia Geldres; Stephanie Choi; Stephen M Hewitt; Steven A Feldman; James N Kochenderfer Journal: Mol Ther Date: 2020-10-14 Impact factor: 11.454